We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Development Agreement Initiated for Radiation Therapy Cancer Treatment

By HospiMedica International staff writers
Posted on 23 Jan 2011
Calypso Medical Technologies, Inc. More...
(Seattle, WA, USA), a developer of real-time localization technology used for the precise tracking of tumors, and Elekta (Stockholm, Sweden), a manufacturer of medical devices and software for treating cancer, announced a master development agreement to jointly develop products integrating the Calypso system with Elekta's radiotherapy treatment technologies.

"Integrating the Calypso system into Elekta's world-class radiotherapy technologies may facilitate the development of innovative treatment modalities for treating prostate cancer along with more problematic radiation therapy targets, such as the pancreas and lung," said Edward Vertatschitsch, PhD, president and chief executive officer of Calypso Medical. "Near term development efforts include creating connectivity between the linear accelerator and the Calypso system for patient positioning during radiation delivery, which automates the process of repositioning the treatment couch when the tumor moves out of a prescribed motion threshold. This agreement will also provide the framework for the potential development of real-time automated correction, a future capability with feasibility work already in progress at both companies, which enables motion management with the tumor target based on real-time tracking data provided by the Calypso system."

"Clinicians around the world, including The Royal Marsden in London [UK], the world's first medical center dedicated to cancer treatment, are utilizing the Calypso system with our linear accelerators to optimize treatment for prostate cancer patients," said Jill Stief, director, product management, oncology systems at Elekta. "Effectively accounting for tumor motion may lead to improved treatment outcomes and patient quality-of-life."

The Calypso system is complementary to Elekta's sophisticated technology for delivering intensity-modulated radiotherapy (IMRT), including Elekta Synergy and Precise linear accelerators. As one of the world's leading suppliers of linear accelerators and oncology software solutions, Elekta is committed to providing clinicians with open-systems connectivity to integrate third-party technologies. "In addition to Elekta's existing initiatives for localization and motion management, this agreement will allow us to leverage synergies in our respective technologies," added Ms. Stief.

"Adapting treatment for tumor motion is vitally important in maximizing the therapeutic value of radiotherapy while minimizing side effects," said Seth Rosenthal, MD, a radiation oncologist at Radiological Associates of Sacramento (Sacramento, CA, USA). "The complementary nature of Calypso's real-time tracking technology and Elekta's highly efficient linear accelerator has improved our ability to detect prostate motion and more accurately deliver radiation."

The objective of external beam radiation therapy is to focus the radiation beam on the tumor while avoiding the irradiation of surrounding healthy tissue. However, internal organ motion may cause the radiation to miss its intended target. The Calypso system, with its global positioning system (GPS) for the Body technology, utilizes miniature implanted Beacon transponders to provide precise, continuous information on the location of the tumor in real-time during external beam radiation therapy. In contrast to other tumor targeting solutions, the Calypso system provides tumor position information objectively and without ionizing radiation, thereby enabling an increase in the radiation delivered to the tumor while reducing radiation misapplied to normal tissue. The Calypso system is installed in more than 100 leading medical centers worldwide.

A May 2010 study published in the journal Urology [Assessing the Impact of Margin Reduction (AIM)], demonstrated that patients whose radiation delivery was guided by the Calypso system experienced a significant decrease in the side effects compared to patients whose radiation treatment did not include Calypso.

Related Links:
Calypso Medical Technologies
Elekta


Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Digital X-Ray Detector Panel
Acuity G4
PACS Workstation
PaxeraView PRO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.